title: Hepatitis B seroprevalence in HIV-infected patients consulting in a public day care unit in Bobo Dioulasso, Burkina Faso.
abstract: OBJECTIVE
  The authors had for aim to assess the prevalence of hepatitis B co-infection in a cohort of HIV-infected patients, routinely followed-up at the Day Care Unit of the Bobo Dioulasso Sanou Souro University Hospital, Burkina Faso.
  
  
  METHODS
  The Elisa technique was used to dose HBs antigen (AgHBs), antibodies anti-HBs and anti-HBc in all the patients followed by the biological laboratory, from October to December 2008.
  
  
  RESULTS
  The AgHBs prevalence was 12.7% [CI at 95%: 10.7-15.0%] and men were slightly more likely to be positive for AgHBs than women (16.5% [12.0-21.9%] versus 11.6% [9.4-14.1%]; P=0.047); 83.3% of the patients [80.8-85.6%] were positive for hepatitis B core antibody, and 32.6% [29.7-35.6%] for hepatitis B surface antibody; 29.9% of the patients [27.1-32.8%] had a complete profile of former hepatitis B infection, 41.3% [38.2-44.4%] expressed core antibodies only; 13.8% [11.7-16.0%] had a negative serological test, and 2.3% [1.5-3.4%] presented a vaccinal immunity.
  
  
  CONCLUSIONS
  These results stress the usefulness of screening for hepatitis B in all HIV-infected patients, along with the initial biological tests. This would help adapt HIV treatment to co-infected patients and to build an expanded program of vaccination for non-immune patients.
authors.affiliation: Département de Médecine, Hôpital de Jour, CHU Souro Sanou Bobo Dioulasso, 01 BP 3437, Bobo Dioulasso, Burkina Faso. badoguil@yahoo.fr
authors.forename: G
authors.initials: G
authors.lastname: Bado
authors.forename: P
authors.initials: P
authors.lastname: Penot
authors.forename: M D
authors.initials: MD
authors.lastname: N'Diaye
authors.forename: C
authors.initials: C
authors.lastname: Amiel
authors.forename: A
authors.initials: A
authors.lastname: Hema
authors.forename: E B
authors.initials: EB
authors.lastname: Kamboulé
authors.forename: J B
authors.initials: JB
authors.lastname: Guiard-Schmid
authors.forename: N F
authors.initials: NF
authors.lastname: Kaboré
authors.forename: L
authors.initials: L
authors.lastname: Slama
authors.forename: A
authors.initials: A
authors.lastname: Bambara
authors.forename: C
authors.initials: C
authors.lastname: Laurent
authors.forename: L
authors.initials: L
authors.lastname: Sangaré
authors.forename: A B
authors.initials: AB
authors.lastname: Sawadogo
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D002050:Burkina Faso / Q000453:epidemiology; D002353:Carrier State / Q000453:epidemiology; D060085:Coinfection; D003631:Day Care, Medical / Q000706:statistics & numerical data*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D006509:Hepatitis B / Q000188:drug therapy / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006511:Hepatitis B Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital / Q000706:statistics & numerical data*; D016036:Seroepidemiologic Studies; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines; D000410:Alanine Transaminase